Rosacea

Clinical trial achieved all three primary objectives and subjects completed 16-week treatment with no significant safety issues Results indicate that DFD-29 can be safely used for up to 16 weeks with no significant risk of microbiota…

SCOTTSDALE, Ariz., Dec. 20, 2022 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ: DERM) (“Journey Medical”), a commercial-stage biopharmaceutical company focused on the development and commercialization of pharmaceutical products…

SCOTTSDALE, Ariz., March 17, 2022 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ: DERM) (“Journey Medical”), a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical…

Santa Clara, California, Dec. 02, 2021 (GLOBE NEWSWIRE) -- Lockdowns, travel restrictions, and local mandates resulting from COVID-19 complicated medical care for millions of Americans. Seeing a medical provider proved so difficult…

VANCOUVER, British Columbia, Sept. 16, 2021 (GLOBE NEWSWIRE) -- Derm-Biome Pharmaceuticals, Inc, a Vancouver based biopharmaceutical company focused on skin health and healthy ageing, is pleased to announce that two of its topical drugs…

NEW YORK and SCOTTSDALE, Ariz., June 30, 2021 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical”), a partner company of Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), today announced an agreement with Dr. Reddy’s…